Genetic heterogeneity in cardiovascular disease across ancestries: Insights for mechanisms and therapeutic intervention

Abstract

Cardiovascular diseases (CVDs) are complex in their aetiology, arising due to a combination of genetics, lifestyle and environmental factors. By nature of this complexity, different CVDs vary in their molecular mechanisms, clinical presentation and progression. Although extensive efforts are being made to develop novel therapeutics for CVDs, genetic heterogeneity is often overlooked in the development process. By considering molecular mechanisms at an individual and ancestral level, a richer understanding of the influence of environmental and lifestyle factors can be gained and more refined therapeutic interventions can be developed. It is therefore expedient to understand the molecular and clinical heterogeneity in CVDs that exists across different populations. In this review, we highlight how the mechanisms underlying CVDs vary across diverse population ancestry groups due to genetic heterogeneity. We then discuss how such genetic heterogeneity is being leveraged to inform therapeutic interventions and personalised medicine, highlighting examples across the CVD spectrum. Finally, we present an overview of how polygenic risk scores and Mendelian randomisation can foster more robust insight into disease mechanisms and therapeutic intervention in diverse populations. Fulfilment of the vision of precision medicine requires more exhaustive leveraging of the genetic variability across diverse ancestry populations to improve our understanding of disease onset, progression and response to therapeutic intervention.

Eliminating hypertension disparities in U.S. non-Hispanic black adults: current and emerging interventions

“…Previous suggestions showed that first-line antihypertensive regimens differed based on BP-lowering in black individuals, with a preference for calcium channel blockers or diuretics over angiotensin-converting inhibitors or angiotensin receptor blockers. This approach does not consider the need for combination therapy, particularly in fixed doses, for most adults with hypertension, which removes any difference across self-identified race [39].…”

Introducing Cambridge prisms: Precision medicine

“…The latest developments to be clinically adopted by specialism have been reviewed for the launch of the journal. These articles highlight some of the greatest achievements of precision medicine to date, including within cardiology (Soremekun, 2023 ), neurodegenerative diseases (Tsoi et al, 2023 ), oncology (Chamba, 2023 ; McGough, 2023 ), mitochondrial medicine (Chinnery, 2022 ), and also more recent areas of study including blood type susceptibility from severe disease with COVID-19 (Ellinghaus, 2023 ).…”